Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Combinations and uses thereof

An antibody and sequence technology, applied in the field of combination and its application, can solve problems such as poor prognosis of cancer

Active Publication Date: 2018-04-17
MORFOZIS AG
View PDF34 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0015] Clearly, despite recent advances in the discovery and development of anticancer agents, many forms of cancer involving CD19-expressing tumors still have a poor prognosis

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Combinations and uses thereof
  • Combinations and uses thereof
  • Combinations and uses thereof

Examples

Experimental program
Comparison scheme
Effect test

specific Embodiment approach

[0069] One aspect of the disclosure is a combination of a CD19 specific antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia. In an embodiment, the combination is synergistic.

[0070] Herein, combinations of exemplified anti-CD19 antibodies and Idelalisib act synergistically in in vitro models associated with CLL. Since CLL is a B cell related disease and CD19 is highly expressed on B cells, the exemplified combinations should have the same mechanism of action and should also be synergistic in the treatment of other B cell related disorders such as NHL and ALL. Thus, combinations of exemplary CD19-specific antibodies and Idelalisib should be effective in the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia in humans. Clinical trials will demonstrate the expected efficacy of the exemplary CD19-specific antibody in com...

Embodiment 1

[0094] Example 1: Cytotoxicity against MEC-1 cells using MOR00208 and Idelalisib alone and in combination

[0095] Material

[0096] Cell lines: chronic B-cell leukemia cell line MEC-1 cells (DSMZ#ACC497); mantle cell lymphoma cell line JVM-2 ( CRL-3002); Ramos cells (ATCC No. CRL-1596), a human Burkitt's lymphoma cell; HG-3 (DSMZ #ACC765) and Cll (DSMZ #ACC773) are chronic lymphocytic leukemia cell lines; Su-DHL 6 (DSMZ #ACC572), and U2932 (DSMZ #ACC633) are diffuse large B-cell lymphoma (DLBCL) cell lines; BALL-1 (DSMZ #ACC742) is an acute lymphoblastic leukemia cell line.

[0097] The culture conditions of the used cell lines followed the supplier's information.

[0098] Cell culture medium: Iscove's Modified Dulbecco's medium (IMDM), Invitrogen, catalog number: 31980-048; RPMI1640, Invitrogen, catalog number: 31870-074; GlutaMAX, Invitrogen, catalog number: 35050-38, lot number 1654740; FCS : Sigma Catalog Number: F7524, Lot Number: 111M3396.

[0099] NKs: RPMI16...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present disclosure describes a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia.

Description

technical field [0001] The present disclosure relates to a pharmaceutical combination of an anti-CD19 antibody and a phosphoinositide 3-kinase inhibitor for the treatment of non-Hodgkin's lymphoma, chronic lymphocytic leukemia and / or acute lymphoblastic leukemia. Background technique [0002] B cells are lymphocytes that play an important role in the humoral immune response. They are produced in the bone marrow of most mammals and comprise 5-15% of the circulating lymphoid pool. The main function of B cells is to produce antibodies against various antigens and is an essential component of the adaptive immune system. [0003] Due to their critical role in regulating the immune system, dysregulation of B cells has been linked to various diseases such as lymphoma and leukemia. These diseases include non-Hodgkin's lymphoma ("NHL"), chronic lymphocytic leukemia ("CLL") and acute lymphoblastic leukemia ("ALL"). [0004] NHL is a heterogeneous malignancy derived from lymphocytes...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K39/395C07K16/28
CPCA61K45/06A61K39/3955A61K31/52A61P35/00A61P35/02A61K2300/00A61K39/395C07K16/2803C07K2317/73A61K39/39558C07D403/12C07D473/16C07K2317/565A61K31/505A61K31/519
Inventor J·恩德尔M·温德尔里奇R·博克斯哈默
Owner MORFOZIS AG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com